|
KMID : 1022820160070020049
|
|
Journal of Multiple Sclerosis and Neuroimmunology
2016 Volume.7 No. 2 p.49 ~ p.54
|
|
|
Alemtuzumab in the Treatment of Multiple Sclerosis
|
|
Oh Jee-Young
|
|
|
Abstract
|
|
|
|
Alemtuzumab is a humanized monoclonal antibody against CD52 and is recently approved for the second-line therapy of active relapse-remitting multiple sclerosis in Korea. Alemtuzumab leads to a rapid and long-lasting depletion of peripheral T and B cells with repopulation of immune cell composition resulting in the rebalancing of immune-tolerance network. However, it has a considerable adverse effects including infusion associated reaction, infection, and secondary autoimmune disease requiring close and regular monitoring during and for 4 years after the final infusion cycle. This review will provide a summary of mechanism of action, data from the pivotal clinical studies, and safety profiles of alemtuzumab.
|
|
|
KEYWORD
|
|
|
Alemtuzumab, CD52, Monoclonal antibody, Multiple sclerosis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|